Hydrofarm Group (HYFM) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Net sales declined 13.1% year-over-year to $54.8 million, mainly due to lower volume/mix and pricing declines from cannabis industry oversupply.
Gross profit margin fell to 19.8% from 23.0% year-over-year; adjusted gross profit margin decreased to 24.4% from 27.0%.
Net loss widened to $23.5 million from $12.9 million, primarily due to an $11.5 million non-cash loss on the IGE Asset Sale.
Restructuring and cost-saving initiatives led to a 20% reduction in SG&A expenses, supporting positive adjusted EBITDA for the fourth time in five quarters.
Cash and cash equivalents stood at $30.3 million as of June 30, 2024, with no borrowings under the revolving credit facility.
Financial highlights
Q2 2024 net sales: $54.8 million (down 13.1% year-over-year); six months: $109.0 million (down 13.0%).
Adjusted gross profit was $13.3 million (24.4% of net sales), down from $17 million (27%) last year.
Adjusted EBITDA was $1.7 million, compared to $2.5 million in the prior year period.
Free cash flow for Q2 was $3.4 million, with operating cash flow of $3.8 million and capex of $0.4 million.
Principal balance on term loan was $120.2 million; $20 million available on revolving credit facility.
Outlook and guidance
Reaffirmed 2024 outlook: net sales to decrease low to high teens percent, positive adjusted EBITDA and free cash flow expected.
Capital expenditures guidance lowered to $3.5–$4.5 million for 2024.
Expects stronger profitability in Q3 than Q4 due to seasonality, with overall margin expansion anticipated in the second half.
Additional restructuring charges in the second half of 2024 may exceed $2 million; annual cost savings from restructuring estimated at over $2 million.
Anticipates improved year-over-year adjusted gross profit margin from cost savings and minimal non-restructuring charges.
Latest events from Hydrofarm Group
- Net sales fell 32.7% and a major impairment drove a $242M net loss amid ongoing restructuring.HYFM
Q4 202527 Mar 2026 - Gross margin improved to 19.4% as net loss narrowed and 2024 outlook was reaffirmed.HYFM
Q3 202416 Jan 2026 - Sales and profit fell in 2024, but cost cuts and brand mix support margin and cash flow gains in 2025.HYFM
Q4 202424 Dec 2025 - Shelf registration enables up to $50M in securities for growth and strategic flexibility.HYFM
Registration Filing16 Dec 2025 - Director elections, executive pay, and auditor ratification headline the 2025 annual meeting.HYFM
Proxy Filing1 Dec 2025 - Proxy statement covers annual meeting proposals and confirms no major capital changes.HYFM
Proxy Filing1 Dec 2025 - Annual proxy statement details routine voting matters for shareholders.HYFM
Proxy Filing1 Dec 2025 - Sales and margins fell 25% as industry headwinds and restructuring drove guidance withdrawal.HYFM
Q1 202526 Nov 2025 - Sales and margins fell, but restructuring and cost cuts drove improved cash flow and outlook.HYFM
Q2 202523 Nov 2025